Cuproptosis
Cuproptosis is a form of regulated cell death driven by intracellular copper accumulation acting on the mitochondria.
Cuproptosis is a form of regulated cell death driven by intracellular copper accumulation acting on the mitochondria. Its defining mechanism is unusual among cell-death pathways in that it has no dedicated executioner protein: copper binds directly to the lipoyl moieties of tricarboxylic acid (TCA) cycle enzymes, most critically dihydrolipoamide S-acetyltransferase (DLAT), causing them to aggregate. The aggregated, lipoylated proteins are themselves the toxic species, and their accumulation coincides with destabilization of iron–sulfur cluster proteins, blocking pyruvate entry into the TCA cycle and producing a proteotoxic mitochondrial crisis that kills the cell. Ferredoxin 1 (FDX1) is required at two points — reducing Cu²⁺ to the more reactive Cu⁺ and supporting protein lipoylation — which makes it the principal determinant of susceptibility, alongside the copper transporters SLC31A1 (CTR1) for import and ATP7A for efflux.
Because the death depends on lipoylated TCA enzymes being present and active, it selectively kills cells that respire: tumors relying on oxidative phosphorylation are sensitive, while glycolytic cells largely resist, and the same lesion can be induced experimentally with copper ionophores such as elesclomol that carry copper past normal import controls. This metabolic dependency is what distinguishes cuproptosis mechanistically from ferroptosis, apoptosis and pyroptosis, and what makes it attractive as a way to attack tumors selected by metabolic state rather than by mutation, potentially circumventing conventional resistance.
Its significance extends beyond oncology. copper overload injures neurons and underlies Wilson disease, in which failure of hepatic copper export produces liver and neurological damage, and cuproptosis has been implicated in subarachnoid hemorrhage, preeclampsia and fibroblast-driven fibrotic disease including endometriosis. Its capacity to elicit immunogenic cell death — releasing damage-associated molecular patterns that stimulate dendritic cells, macrophages and CD8+ T cells — places it at the intersection of metabolic disruption and antitumor immunity, and is the rationale for combining copper-directed agents with immunotherapy.
Where the papers sit
14 papers from the last 6 months study cuproptosis directly · updated from PubMed 10 Nov 2026
Study type 0 clinical trials · 1 human data · 12 preclinical · 1 unclassified
Themes 3 themes
-
Cuproptosis and Cancer Immunity
Cuproptosis is being paired with radiotherapy, sunitinib, and immunotherapy to overcome resistant tumors. Copper nanoparticles, hydrogels, nanocapsules, and bioorthogonal systems aim to amplify tumor killing while reshaping the tumor microenvironment. Immunogenic cell death and damage-associated molecular patterns recur as links to stronger antitumor immunity. Mitochondrial energy metabolism remains a key determinant of response, especially in thyroid, renal, and triple-negative breast cancers.
8 papers · 57.1%
-
Copper Homeostasis and Cell Injury
Copper homeostasis and mitochondrial oxidative stress connect cuproptosis-related injury across neural, cardiac, and lung cancer settings. SLC31A1 and FDX1 recur as mechanistic nodes linking copper transport to mitochondrial damage. Luteolin is explored as protection against doxorubicin cardiotoxicity, whereas FOSL1-mediated signaling is targeted to sensitize radioresistant non-small cell lung cancer. The shared biology is clearer than any single therapeutic direction.
3 papers · 21.4%
-
Photothermal Cuproptosis Therapy
Multimodal nanotherapies are combining cuproptosis with photothermal treatment or disulfidptosis rather than relying on copper toxicity alone. Hyaluronic acid-coated silica nanoparticles target lung tumors, while photothermal nanomachines seek controlled activation in tumor cells. Oxygen-pump microneedles extend the strategy to melanoma and immunotherapy. The central aim is coordinated redox and heat stress that improves tumor killing and immune response.
3 papers · 21.4%
Papers
The 14 papers from the last 6 months that study cuproptosis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cuproptosis and Cancer Immunity (8)
- Cuproptosis enters the cancer-immunity circuit. Cell · 20 Aug 2026 PMID 42624074
- A Self-Reinforcing Cuproptosis-Radiotherapy Loop by Copper Carbonate Nanoparticles for Enhanced Immunotherapy. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587511
- Brachytherapy Combined with Cuproptosis-Inducing Radiosensitizer Overcomes Radioresistance in Triple-Negative Breast Cancer. Nano letters · 12 Aug 2026 PMID 42584274
- A Self-Monitoring Single-Atom Copper Nanocapsule for Cascade-Responsive Tumor Cuproptosis Therapy. Angewandte Chemie (International ed. in English) · 6 Jul 2026 PMID 42405495
- Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- Deciphering the interplay between cuproptosis and mitochondrial energy metabolism in thyroid cancer: a multi-omics study for molecular subtyping, prognosis, and tumor microenvironment characterization. Molecular and cellular biochemistry · 19 Jun 2026 PMID 42319714
- A sonopiezoresponsive covalent organic framework-based smart nanoreactor orchestrates in situ bioorthogonal chemistry and cuproptosis for enhanced tumor therapy. Acta biomaterialia · 13 Jun 2026 PMID 42288303
Copper Homeostasis and Cell Injury (3)
- Tanshinone IIA attenuates cognitive impairment in vascular dementia rats by modulating copper homeostasis via the SLC31A1/FDX1 axis. PloS one · 24 Aug 2026 PMID 42636217
- Targeting Activator Protein-1 Transcription Factor Subunit FOSL1-Mediated Cuproptosis Sensitizes Radioresistant Non-Small Cell Lung Cancer. ACS nano · 18 Aug 2026 PMID 42611215
- Metal-dependent cell death in doxorubicin-induced cardiotoxicity and mitigation by luteolin: Network pharmacology and experimental verification. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 30 Jul 2026 PMID 42531631
Photothermal Cuproptosis Therapy (3)
- Oxygen pump microneedles coupling cuproptosis and disulfidptosis to enhance melanoma immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Sept 2026 PMID 42767378
- Photothermal Pulse Output-Nanomachines for Enhanced Cuproptosis in Tumor Cells. ACS applied bio materials · 30 Jun 2026 PMID 42378513
- Hyaluronic acid-camouflaged dendritic silica nanoparticles enable targeted cuproptosis and photothermal therapy for lung cancer. Colloids and surfaces. B, Biointerfaces · 5 Jun 2026 PMID 42247956
By study type
Human data, design not indexed (1)
- Photothermal Pulse Output-Nanomachines for Enhanced Cuproptosis in Tumor Cells. ACS applied bio materials · 30 Jun 2026 PMID 42378513
Preclinical: animal, cell and lab studies (12)
- Oxygen pump microneedles coupling cuproptosis and disulfidptosis to enhance melanoma immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Sept 2026 PMID 42767378
- Tanshinone IIA attenuates cognitive impairment in vascular dementia rats by modulating copper homeostasis via the SLC31A1/FDX1 axis. PloS one · 24 Aug 2026 PMID 42636217
- Cuproptosis enters the cancer-immunity circuit. Cell · 20 Aug 2026 PMID 42624074
- Targeting Activator Protein-1 Transcription Factor Subunit FOSL1-Mediated Cuproptosis Sensitizes Radioresistant Non-Small Cell Lung Cancer. ACS nano · 18 Aug 2026 PMID 42611215
- A Self-Reinforcing Cuproptosis-Radiotherapy Loop by Copper Carbonate Nanoparticles for Enhanced Immunotherapy. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587511
- Brachytherapy Combined with Cuproptosis-Inducing Radiosensitizer Overcomes Radioresistance in Triple-Negative Breast Cancer. Nano letters · 12 Aug 2026 PMID 42584274
- Metal-dependent cell death in doxorubicin-induced cardiotoxicity and mitigation by luteolin: Network pharmacology and experimental verification. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 30 Jul 2026 PMID 42531631
- A Self-Monitoring Single-Atom Copper Nanocapsule for Cascade-Responsive Tumor Cuproptosis Therapy. Angewandte Chemie (International ed. in English) · 6 Jul 2026 PMID 42405495
- Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- A sonopiezoresponsive covalent organic framework-based smart nanoreactor orchestrates in situ bioorthogonal chemistry and cuproptosis for enhanced tumor therapy. Acta biomaterialia · 13 Jun 2026 PMID 42288303
- Hyaluronic acid-camouflaged dendritic silica nanoparticles enable targeted cuproptosis and photothermal therapy for lung cancer. Colloids and surfaces. B, Biointerfaces · 5 Jun 2026 PMID 42247956
Unclassified: not yet indexed with MeSH (1)
- Deciphering the interplay between cuproptosis and mitochondrial energy metabolism in thyroid cancer: a multi-omics study for molecular subtyping, prognosis, and tumor microenvironment characterization. Molecular and cellular biochemistry · 19 Jun 2026 PMID 42319714
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-08-26 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.